65,437 trials
Threatened Preterm Labor
Primary: Evaluate if ACTH Can be Used as a Predictive Marker for Preterm Labor — 23.4; 19.3 pg/ml — p=<0.001
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 8.38; 9.63 months — p=0.217
Asthma · Lung Diseases
Primary: Pulmonary Function as Measured by Normalized FEV1 Over a 4-6 Year Period — 0.6; -0.5; -0.1 percentage of predicted value
Allergic Rhinitis · Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS) — -0.91; -0.63 Score on a scale — p=0.0024
Influenza
Primary: Number of Seroconverted Subjects for Anti- Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains of Quadrivalent Influenza…
Major Depressive Disorder
Primary: Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8 — -11.0; -16.1 Units on a scale — p=<0.00001
Asthma · Airway Obstruction
Primary: FEV1 Peak Effect Within 0 - 24 h Post-dose — 3.56; 3.62; 3.70; 3.62 L
Relapsing Remitting Multiple Sclerosis
Primary: ARR - PDEs — 0.12; 0.16; 0.11 relapses per year
Primary Dysmenorrhea
Primary: Dysmenorrheal Pain Severity — 3.88; 6.31 units on a scale
Depressive Symptoms · Inflammation
Primary: Brief Center for Epidemiologic Studies Depression Scale (CESD) — -3.46; -1.26 units on a scale — p=.039
Heroin Addiction
Primary: Treatment Retention in the Community — 23.1; 91.3; 166.0 Days in community treatment
Epilepsy
Primary: Assessment of Taste Preference — 5.8; 5.8; 7.1 units on a scale (0-10 cm VAS)
Diabetes Mellitus, Type 2
Primary: Postprandial Pulse Wave Velocity (PWV) in Type 2 Diabetes Mellitus (T2DM) Participants at 30 Minutes (Mins) Pre-Breakfast — 10.99; 10.73; 11.56; 11.31 meters per second…
Blindness
Primary: Mean Percent (Prototype / Baseline) Time — 78.7 Percentage of Baseline Performance Time
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Relapse-free Survival — 48 participants